6 completed, 3 recruiting, 2 unknown, 2 withdrawn. 12 Phase 2, 6 Phase 1, 1 Not applicable, 1 Phase 3.
Follow Myxofibrosarcoma: new trials by email Literature Review of Myxofibrosarcoma trials Research Report on Myxofibrosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. Definitive radiotherapy - Soft Tissue Sarcoma (STS), Soft Tissue Sarcoma Adult | Phase 2 | Recruiting | Oslo University Hospital | 40 | 2026-01-26 | 2026-01-28 |
| Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma Biopsy, Chest Computed Tomography, Chest Radiography - Adult Pleomorphic Rhabdomyosarcoma, AJCC Grade 2 Sarcoma | Not applicable | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 1582 | 2025-01-28 | 2024-07-30 |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 139 | 2024-03-27 | 2026-08-03 |
| Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Gemcitabine, 9-ING-41, Docetaxel - Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma | Phase 2 | Withdrawn | Brown University | 2022-03-01 | 2021-12-07 | |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Gemcitabine, Docetaxel, 9-ING-41 - Sarcoma, Soft Tissue Sarcoma | Phase 2 | Withdrawn | Brown University | 2021-09-01 | 2021-07-28 | |
| ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Envafolimab, Ipilimumab - Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | Phase 2 | Unknown | Tracon Pharmaceuticals Inc. | 207 | 2020-12-09 | 2024-05-17 |
| Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma Definitive Surgical Resection, Nanoplexed Poly I:C BO-112, Nivolumab - Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 14 | 2020-10-14 | 2026-03-10 |
| A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg Isolated Limb Infusion, Pembrolizumab, infusion of melphalan and dactinomycin - Sarcoma, Myxofibrosarcoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2020-04-01 | 2026-04-23 |
| Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas DCC-3014, Avelumab - Sarcoma, Advanced Sarcoma | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 32 | 2020-01-22 | 2025-08-28 |
| CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma CAB-AXL-ADC, PD-1 inhibitor - Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | Phase 1 / Phase 2 | Completed | BioAtla, Inc. | 245 | 2018-02-15 | 2025-09-23 |
| Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma | Phase 1 | Completed | OHSU Knight Cancer Institute | 16 | 2017-03-10 | 2023-08-16 |
| Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Sequential chemotherapy - 3 courses of AI, Hypofractionated radiotherapy - Sarcoma, Fibrosarcoma | Phase 2 | Unknown | Maria Sklodowska-Curie National Research Institute of Oncology | 46 | 2017-02-11 | 2021-01-22 |
| Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Dexrazoxane, Doxorubicin - Sarcoma, Soft Tissue, Soft Tissue Sarcoma | Phase 2 | Completed | Washington University School of Medicine | 73 | 2016-02-22 | 2023-11-07 |
| Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Pazopanib, Pazopanib Hydrochloride, Sapanisertib - High Grade Sarcoma, Metastatic Leiomyosarcoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 151 | 2015-11-30 | 2022-08-23 |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide - Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 140 | 2014-08-12 | 2026-06-17 |
| Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Alisertib, Laboratory Biomarker Analysis - Myxofibrosarcoma, Recurrent Adult Soft Tissue Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 72 | 2012-08-22 | 2017-11-30 |
Dermatofibrosarcoma (16) · Histiocytoma, Malignant Fibrous (15) · Sarcoma (14) · Leiomyosarcoma (12) · Liposarcoma (11) · Sarcoma, Synovial (11) · Neurofibrosarcoma (9) · Fibrosarcoma (6) · Hemangiosarcoma (6) · Chondrosarcoma, Extraskeletal Myxoid (3) · Sarcoma, Alveolar Soft Part (3) · Sarcoma, Clear Cell (3) · Bone Neoplasms (2) · Disorders of Sex Development (2) · Histiocytoma, Angiomatoid Fibrous (2)
Neoplasms by Histologic Type (16) · Neoplasms, Connective Tissue (16) · Neoplasms, Connective and Soft Tissue (16) · Neoplasms, Fibrous Tissue (16) · Histiocytoma (15) · Neoplasms (15) · Neoplasms, Muscle Tissue (13) · Fibrosarcoma (10) · Neoplasms, Adipose Tissue (10) · Neoplasms, Nerve Tissue (9) · Nervous System Diseases (9) · Nervous System Neoplasms (9) · Neurofibroma (9) · Neuromuscular Diseases (9) · Peripheral Nervous System Diseases (9)
Doxorubicin (4) · pazopanib (3) · 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (2) · Docetaxel (2) · Gemcitabine (2) · Ifosfamide (2) · Radiation (2) · Radiotherapy (2) · BO-112 (1) · Biopsy (1) · Dactinomycin (1) · Dexrazoxane (1) · Immune Checkpoint Inhibitors (1) · Ipilimumab (1) · MLN 8237 (1)
National Cancer Institute (NCI) (3) · Brown University (2) · Memorial Sloan Kettering Cancer Center (2) · BioAtla, Inc. (1) · ECOG-ACRIN Cancer Research Group (1) · Jonsson Comprehensive Cancer Center (1) · Maria Sklodowska-Curie National Research Institute of Oncology (1) · OHSU Knight Cancer Institute (1) · Oslo University Hospital (1) · St. Jude Children's Research Hospital (1) · Tracon Pharmaceuticals Inc. (1) · Washington University School of Medicine (1)
United States (13) · Canada (1) · Hong Kong (1) · Norway (1) · Poland (1) · Puerto Rico (1) · Taiwan (1) · United Kingdom (1)
Aaron R Weiss (1) · Bradley D DeNardo, MD (1) · Bradley DeNardo, MD (1) · Brian A Van Tine, M.D., Ph.D. (1) · Charles Theuer, MD, PhD (1) · Don S Dizon, MD (1) · Edmund Bartlett, MD (1) · Galina G Lagos, MD (1) · Ivar Hompland, MD, PhD (1) · Jessica Gartrell, MD (1) · Kenneth Cardona (1) · Kjetil Boye, MD, PhD (1) · Lara E Davis (1) · Mark Dickson (1) · Sandra D'Angelo, MD (1)
PMID 27502708, PMID 32702309, PMID 32827353, PMID 34515544, PMID 34722269, PMID 37523624, PMID 38579194, PMID 42194972
U10CA180821 (2), K08CA245181 (1), U10CA031946 (1), U10CA098543 (1), U10CA180830 (1), U10CA180886 (1), UG1CA189828 (1)